Crestline Management, LP

Q4 2017 13F Combination Report, Options Holdings

Signature - Title
John S. Cochran - Vice President
Location
Fort Worth, TX
Options holdings as of
December 31, 2017
Notional value $
$0
Number of holdings
0
Date filed
2/14/2018, 06:14 PM
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s).
Previous filing
Q3 2017 - Nov 14, 2017
Stock holdings
Showing options holdings, see here for stock holdings

Crestline Management, LP didn't report any options holdings as of Q4 2017. Check stock holdings.

Filing 2017 Q4 compared to 2017 Q3 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John S. Cochran Vice President Fort Worth, Texas 2/14/2018

The number of shares in Juno Therapeutics Inc. reflected herein includes 248,330 shares over which Crestline Management, L.P. did not have investment discretion but which Douglas K. Bratton otherwise had ultimate investment discretion. Mr. Bratton also has ultimate investment discretion over Crestline Management, L.P. The number of shares in Denali Therapeutics Inc. reflected herein includes 1,111,798 shares held by Neuro Line Partners, L.P. over which Bratton Capital Management, L.P. and Bratton Capital, Inc. have investment discretion. Mr. Bratton has ultimate investment discretion over Bratton Capital Management, L.P., Bratton Capital, Inc. and Crestline Management, L.P.

List of Other Managers Reporting for Crestline Management, LP:

Name Holdings Value Location File Number
Oribel Capital Management, LP $916M New York, NY 028-17769